ArticleMolecular genetics and genomics : MGG2026
Flemboda artificial intelligence: hybrid fuzzy-convolutional neural network for efficient chromosome abnormality classification.
Article in Molecular genetics and genomics : MGG, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromosomal abnormality detection is a fundamental task in clinical genetics, as accurate identification of structural and numerical defects is essential for reliable diagnosis and treatment planning. However, many existing learning-based approaches failed to effectively capture diverse discriminative features, limiting their classification performance. To address this challenge, this study proposes FLEMBODA AI, an advanced computational framework designed to enhance the efficiency, accuracy, and robustness of automated chromosome defect detection. At first, the karyotype image is collected. Then, the input is augmented and pre-processed using normalization and a G-bending enhancement approach to ensure that the model's effectiveness generalizes across diverse datasets. After that, the chromosomes are segmented from the pre-processed image using a U-Net approach to isolate chromosomes from the karyotype image. Then, the segmented chromosomes are given as input to the Hybrid Fuzzy-Convolutional Neural Network (Hybrid Fuzzy-CNN) approach. In this, the CNN model performs the Feature Extraction (FE) process, and the Fuzzy logic is used for the classification of chromosomal abnormalities. Here, the VGG-16 is used for weight assignment for the classification. Then, using the Mask Region-centric CNN (Mask R-CNN), chromosome defect localization is performed. Experimental results demonstrate that FLEMBODA AI achieves a recall of 95.3%, precision of 94.8%, and an F1-score of 95.0%, outperforming baseline models. Additionally, the U-Net segmentation model attains an accuracy of 93.8%, contributing significantly to improved abnormality localization and classification performance. Overall, the proposed FLEMBODA AI framework provides a reliable as well as effective solution for automated chromosomal abnormality detection, with strong potential for application in clinical diagnostics and future large-scale genetic analysis systems.
Indexed as
Identifiers
41559480What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.